

Claims:

1. A compound of formula I:



(I) or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, which is



.

3. The compound of claim 1 in the form of a pharmaceutically acceptable salt.


4. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 2.

5. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 3.

6. Use of the compound according to claim 1, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a metabolic-related disease.


7. The use of claim 6, wherein the metabolic-related disease is selected from diabetes, obesity or non-alcoholic fatty liver disease-related diseases, or other related diseases caused by diabetes, obesity or non-alcoholic fatty liver disease.

8. A compound of formula II:



(II) or a pharmaceutically acceptable salt thereof.

9. A compound according to claim 8, which is



.

10. The compound of claim 8 in the form of a pharmaceutically acceptable salt.


11. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 9.

12. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 10.

13. Use of the compound according to claim 8, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a metabolic-related disease.


14. The use of claim 13, wherein the metabolic-related disease is selected from diabetes, obesity or non-alcoholic fatty liver disease-related diseases, or other related diseases caused by diabetes, obesity or non-alcoholic fatty liver disease.

15. A compound of formula III:



(III) or a pharmaceutically acceptable salt thereof.

16. A compound according to claim 15, which is



.

17. The compound of claim 15 in the form of a pharmaceutically acceptable salt.


18. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 16.

19. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 17.

20. Use of the compound according to claim 15, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a metabolic-related disease.


21. The use of claim 20, wherein the metabolic-related disease is selected from diabetes, obesity or non-alcoholic fatty liver disease-related diseases, or other related diseases caused by diabetes, obesity or non-alcoholic fatty liver disease.

22. A compound of formula IV:



(IV) or a pharmaceutically acceptable salt thereof.

23. A compound according to claim 22, which is



.

24. The compound of claim 22 in the form of a pharmaceutically acceptable salt.


25. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 23.

26. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 24.

27. Use of the compound according to claim 22, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a metabolic-related disease.


28. The use of claim 27, wherein the metabolic-related disease is selected from diabetes, obesity or non-alcoholic fatty liver disease-related diseases, or other related diseases caused by diabetes, obesity or non-alcoholic fatty liver disease.

29. A compound of formula V:



(V) or a pharmaceutically acceptable salt thereof.

30. A compound according to claim 29, which is



.

31. The compound of claim 29 in the form of a pharmaceutically acceptable salt.

32. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 30.

33. A pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) the compound of claim 31.

34. Use of the compound according to claim 29, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for the treatment of a metabolic-related disease.

35. The use of claim 34, wherein the metabolic-related disease is selected from diabetes, obesity or non-alcoholic fatty liver disease-related diseases, or other related diseases caused by diabetes, obesity or non-alcoholic fatty liver disease.

36. The compound according to any one of claims 1, 8, 15, 22 or 29, or a pharmaceutically acceptable salt thereof, for use in therapy.